Clinical Trials Browser

Interventional × Endometrial Neoplasms × durvalumab × Clear all

NCT06746116 2026-04-16

DUoENDE

Phase 3 Active not recruiting

Endometrial Neoplasms

NCT03682289 2026-04-15

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Phase 2 Recruiting

GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

NCT04065269 2026-02-20

ATARI

Phase 2 Active not recruiting

GynecologicSarcoma

Carcinosarcoma, Uterine Cervical Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT04269200 2025-12-23

DUO-E

Phase 3 Active not recruiting

805 enrolled 18 charts 2 FDA

Endometrial Neoplasms

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03277482 2025-05-31

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Phase 1 Terminated

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT05255653 2024-11-29

RAINBO

Phase 2/3 Recruiting

Endometrial Neoplasms

NCT06680739 2024-11-08

SERPENTINE

Phase 2 Recruiting

GastrointestinalGynecologic

Colorectal Neoplasms, Endometrial Neoplasms

NCT03015129 2024-02-06

A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer

Phase 2 Completed

80 enrolled 9 charts

Recurrence, Endometrial Neoplasms

NCT03951415 2021-04-01

DOMEC

Phase 2 Unknown

Uterine Neoplasms, Endometrial Neoplasms

NCT02725489 2021-01-27

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

Phase 2 Completed

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms

NCT04444193 2020-06-23

Dulect2020-2

Phase NA Unknown

Endometrial Neoplasms